Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial.

A single dose of the apolipoprotein (apo)A-I mimetic peptide D-4F rendered high-density lipoprotein (HDL) less inflammatory, motivating the first multiple-dose study. We aimed to assess safety/tolerability, pharmacokinetics, and pharmacodynamics of daily, orally administered D-4F. High-risk coronary heart disease (CHD) subjects added double-blinded placebo or D-4F to statin for 13 days, randomly assigned 1:3 to ascending cohorts of 100, 300, then 500mg (n = 62; 46 men/16 women). D-4F was safe and well-tolerated. Mean +/- SD plasma D-4F area under the curve (AUC, 0-8h) was 6.9 +/- 5.7 ng/mL*h (100mg), 22.7 +/- 19.6 ng/mL*h (300mg), and 104.0 +/- 60.9 ng/mL*h (500mg) among men, higher among women. Whereas placebo dropped HDL inflammatory index (HII) 28% 8h postdose (range, 1.25-0.86), 300-500mg D-4F effectively halved HII: 1.35-0.57 and 1.22-0.63, respectively (P < 0.03 vs. placebo). Oral D-4F peptide dose predicted HII suppression, whereas plasma D-4F exposure was dissociated, suggesting plasma penetration is unnecessary. In conclusion, oral D-4F dosing rendered HDL less inflammatory, affirming oral D-4F as a potential therapy to improve HDL function.